PSTVCERENOME, INC.

Is Cerenome struggling financially?

Yes, by its own account. Cerenome told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 4months

    If the burn speeds up

    Empty by Oct 2026

  • 6months

    If it eases off

    Empty by Dec 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$8.6M

÷

Cash burned over the last 12 months

$20.8M

What Cerenome told the SEC

…capital in the future. The Company’s inability to raise additional cash would have a material and adverse impact on its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. As disclosed in more detail in Note 12 Stockholders' Equity , the Company has entered into various financing agreements to raise capital. The Company continues to seek additional…

CERENOME, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 28% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt